SG11201807720TA - Methods and systems for determining antibiotic susceptibility - Google Patents

Methods and systems for determining antibiotic susceptibility

Info

Publication number
SG11201807720TA
SG11201807720TA SG11201807720TA SG11201807720TA SG11201807720TA SG 11201807720T A SG11201807720T A SG 11201807720TA SG 11201807720T A SG11201807720T A SG 11201807720TA SG 11201807720T A SG11201807720T A SG 11201807720TA SG 11201807720T A SG11201807720T A SG 11201807720TA
Authority
SG
Singapore
Prior art keywords
international
march
pct
systems
methods
Prior art date
Application number
SG11201807720TA
Inventor
George Terrance Walker
Tony Rockweiler
Original Assignee
Opgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opgen Inc filed Critical Opgen Inc
Publication of SG11201807720TA publication Critical patent/SG11201807720TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30—Data warehousing; Computing architectures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioethics (AREA)
  • Databases & Information Systems (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111110110011111111111111101111011111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...1 WO 2017/156037 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12Q 1/68 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, Fk GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/021209 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 7 March 2017 (07.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/304,807 7 March 2016 (07.03.2016) US kind of regional protection available): ARIPO (BW, GH, 62/305,247 8 March 2016 (08.03.2016) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: OPGEN, INC. [US/US]; 708 Quince Orchard TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Road, Gaithersburg, Maryland 20878 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Inventors: WALKER, George Terrance; 6480 Wiscon- sin Avenue #1123, Chevy Chase, Maryland 20815 (US). SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). ROCKWEILER, Tony; 2001 N. Adams Street #829, Ar- lington, Virginia 22201 (US). Declarations under Rule 4.17: (74) Agents: ELRIFI, Ivor, R. et al.; Cooley LLP, 1299 — as to applicant's entitlement to apply for and be granted a Pennsylvania Avenue, NW, Suite 700, Washington, Dis- patent (Rule 4.1700) trict of Columbia 20004 (US). Published: Designated States (unless otherwise indicated, for every with international search report (Art. 21(3)) kind of national protection available): AE, AG, AL, AM, (81) — Title: METHODS AND SYSTEMS FOR DETERMINING ANTIBIOTIC SUSCEPTIBILITY (54) Figure 1 _ . — Il IN en © ir) , 11 IN 1-1 (57) : The present invention provides methods, systems, and kits for determining an appropriate therapeutic regimen for 0 treating an infection caused by antibiotic resistant bacteria. N O
SG11201807720TA 2016-03-07 2017-03-07 Methods and systems for determining antibiotic susceptibility SG11201807720TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662304807P 2016-03-07 2016-03-07
US201662305247P 2016-03-08 2016-03-08
PCT/US2017/021209 WO2017156037A1 (en) 2016-03-07 2017-03-07 Methods and systems for determining antibiotic susceptibility

Publications (1)

Publication Number Publication Date
SG11201807720TA true SG11201807720TA (en) 2018-10-30

Family

ID=58398274

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807720TA SG11201807720TA (en) 2016-03-07 2017-03-07 Methods and systems for determining antibiotic susceptibility

Country Status (8)

Country Link
US (1) US20170253917A1 (en)
EP (1) EP3426800A1 (en)
KR (1) KR20190010533A (en)
CN (1) CN109196122A (en)
CA (1) CA3016632A1 (en)
IL (1) IL261651A (en)
SG (1) SG11201807720TA (en)
WO (1) WO2017156037A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015229077A1 (en) 2014-03-13 2016-09-29 Opgen, Inc. Methods of detecting multi-drug resistant organisms
WO2015184017A1 (en) 2014-05-27 2015-12-03 Opgen, Inc. Systems, apparatus, and methods for generating and analyzing resistome profiles
EP3861129A4 (en) * 2018-10-02 2022-07-20 BioFire Diagnostics, LLC Bacterial response
CN109576383B (en) * 2018-12-14 2022-11-11 广西大学 Method for constructing mouse disease model infected with bacterial septicemia and judging disease condition
CN110129460B (en) * 2019-03-21 2023-07-04 广西壮族自治区动物疫病预防控制中心 Double qPCR (quantitative polymerase chain reaction) kit for two drug-resistant genes of super bacteria and detection method
CN110184364A (en) * 2019-05-14 2019-08-30 天津科技大学 A kind of multi-PCR detection method and application for detecting the legionella pneumophilia of carrying Sulfonamides-resistant genes
CN110408712B (en) * 2019-07-29 2023-07-04 上海市农业科学院 Quick screening kit and primer for quinolone drug resistance genes in bacteria
CN110904249B (en) * 2019-10-28 2023-04-25 杭州千基生物科技有限公司 Kit and method for detecting nucleic acid of bacterial drug-resistant gene quantum dot chip
KR102279822B1 (en) * 2019-11-28 2021-07-19 가톨릭대학교 산학협력단 Composition for detecting antibiotic resistant pathogen of sepsis and uses thereof
US20210340599A1 (en) * 2020-05-04 2021-11-04 International Business Machines Corporation Predicting antibiotic resistance and complementary antibiotic combinations
CN114898800B (en) * 2022-07-14 2022-09-16 中国医学科学院北京协和医院 Method and system for predicting sensitivity of klebsiella pneumoniae to ceftriaxone
CN115862730B (en) * 2023-02-06 2023-06-02 中国医学科学院北京协和医院 System and method for predicting sensitivity of Klebsiella to cefoxitin
CN116732209B (en) * 2023-08-04 2023-10-13 广东省农业科学院农业质量标准与监测技术研究所 Kit and method for simultaneously detecting drug resistance genes ISCR2 and FLOR based on digital PCR technology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183679A1 (en) * 2010-09-10 2013-07-18 Marie-Cecile Ploy Method for detecting the presence of bacterial strains resistant to antibiotics in a biological sample
WO2015114094A1 (en) * 2014-01-30 2015-08-06 Siemens Aktiengesellschaft Genetic resistance testing
AU2015229077A1 (en) 2014-03-13 2016-09-29 Opgen, Inc. Methods of detecting multi-drug resistant organisms
WO2015184017A1 (en) 2014-05-27 2015-12-03 Opgen, Inc. Systems, apparatus, and methods for generating and analyzing resistome profiles

Also Published As

Publication number Publication date
CN109196122A (en) 2019-01-11
IL261651A (en) 2018-10-31
US20170253917A1 (en) 2017-09-07
KR20190010533A (en) 2019-01-30
CA3016632A1 (en) 2017-09-14
WO2017156037A1 (en) 2017-09-14
EP3426800A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811640SA (en) Multispecific antigen binding proteins and methods of use thereof
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201901747VA (en) Inhibitors of cellular metabolic processes
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201903582UA (en) Settlement method, entrance control method, and apparatus
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201804721SA (en) Modulators of complement activity
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201901458RA (en) Systems and methods for removing fluid from a tray in an assembly line grow pod
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201408171SA (en) Fbxo3 inhibitors
SG11201809473QA (en) Humanized anti-basigin antibodies and the use thereof
SG11201809882XA (en) Pharmaceutical combinations for treating cancer